Research programme: anti-G protein-coupled receptor antibodies - Abilita Bio

Drug Profile

Research programme: anti-G protein-coupled receptor antibodies - Abilita Bio

Alternative Names: Anti-G protein-coupled receptor antibodies - Ab3; Anti-G protein-coupled receptor antibodies - Ab6; Anti-G protein-coupled receptor antibodies - CCR7; Anti-G protein-coupled receptor antibodies - EP2; Anti-G protein-coupled receptor antibodies - EP4

Latest Information Update: 03 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abilita Bio
  • Class Antibodies
  • Mechanism of Action CCR7 receptor modulators; G protein-coupled receptor antagonists; Prostaglandin E EP2 receptor modulators; Prostaglandin E EP4 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Breast cancer; Cancer; CNS disorders

Most Recent Events

  • 30 Jan 2017 Abilita Bio enters into a research collaboration with an undisclosed pharmaceutical company to develop anti-G- protein-coupled receptor antibodies
  • 22 Sep 2016 Research programme: anti-G protein-coupled receptor antibodies - Abilita Bio is available for licensing as of 22 Sep 2016. http://www.abilitabio.com/
  • 20 Sep 2016 Abilita Bio enters into a multi-target proof of concept agreement with an undisclosed global pharmaceutical company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top